Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response

• Main Authors: Sarabjot Pabla (Author), R. J. Seager (Author), Erik Van Roey (Author), Shuang Gao (Author), Carrie Hoefer (Author), Mary K. Nesline (Author), Paul DePietro (Author), Blake Burgher (Author), Jonathan Andreas (Author), Vincent Giamo (Author), Yirong Wang (Author), Felicia L. Lenzo (Author), Margot Schoenborn (Author), Shengle Zhang (Author), Roger Klein (Author), Sean T. Glenn (Author), Jeffrey M. Conroy (Author)
• Format: Book
• Published: BMC, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Contemporary to the rapidly evolving landscape of cancer immunotherapy is the equally changing understanding of immune tumor microenvironments (TMEs) which is crucial to the success of these therapies. Their reliance on a robust host immune response necessitates clinical grade me...